ALZINOVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.156 SEK | -32.00% |
|
-33.33% | -61.91% |
| Apr. 25 | Sweden’s Alzinova Says CEO to Step Down by July-end | MT |
| Apr. 25 | Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâs disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -61.91% | 4.7M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALZ Stock
- News Alzinova AB
- EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate
